contrast, in PC3 cells, there was only a significant (3-fold) upregulation of ProL1 after 24h of hypoxia, with other markers of the hypoxic response (Hif1a and VEGF) significantly activated after 5h. CONCLUSIONS: For the first time we report up-regulation of the opiorphin gene (ProL1) in PrCa. Opiorphin is a mediator of the hypoxic response in certain cell types. We demonstrate hypoxic upregulation of ProL1 in two PrCa cell lines. Early upregulation in LnCaP cells, prior to other known markers of the hypoxic response (Hif1a and VEGF) suggests in certain PrCa cells (androgen dependent) ProL1 may play a role in regulating downstream modulators of the hypoxic response. Taken together, these results suggest opiorphin may play a role in overcoming the hypoxic environment in certain PrCa tumors and might therefore represent a novel therapeutic for PrCa.
INTRODUCTION AND OBJECTIVES: The risk of developing venous thromboembolic events (VTE) is increased up to 4-fold in in men diagnosed with metastatic prostate cancer (PCa) . While the precise reasons for this are unknown previous work has established the capacity of platelets (clot initiators) to absorb factors from the bloodstream that may alter platelet functions. Notably, one such factor, cell free DNA (cfDNA) has been shown to strongly correlate with disease severity and outcome. In this study, we sought to examine the effects of cfDNA from men with aggressive PCa on platelets in the context of clot formation and disease progression.
METHODS: Platelets were isolated from venous blood of 10 men with metastatic castration resistant prostate cancer (mCRPC) . Platelet aggregation in response to agonists (i.e. thrombin and collagen) was established using platelet aggregometer. Platelet ability to bind to cancer cells (in vitro) was determined using flow cytometry. Platelet effect on prostate tumor growth in vivo was assessed using human platelet transfusions into 3 different PCa mouse models (intracardiac, subcutaneous, and orthotopic) in combination with standard bioluminescence techniques.
RESULTS: We assessed the effects of tumor associated nucleic acids on circulating platelets. We found that PCa derived cfDNA -loaded platelets were more reactive to agonists (thrombin and collagen), vs. unloaded platelets, making them more susceptible to spontaneous clot formation. We established that platelets from men with mCRPC (10 men) were significantly (p<0.001) more adherent to cancer cells in vitro as compared to platelets from healthy controls. Addition of nucleic acids (i.e. DNA) to healthy donor platelets in vitro converted them to be more thrombogenic and similar to platelets from men with mCRPC. Finally, we observed that platelets from men with mCRPC strongly induced cell proliferation and tumor growth in vivo (p<0.005), as compared to platelets from healthy controls.
CONCLUSIONS: High levels of cancer associated cfDNA have been previously demonstrated to correlate with poor prognosis and increased risk of VTE in men with PCa. Intriguingly, we found that PCa associated cfDNA modulates platelet behavior, revealing, for the first time, a potential molecular basis for Trousseau syndrome in PCa. Further, our findings also shed new light on how cfDNA may alter cancer growth via modulating platelets in the tumor microenvironment. Taken together, our study provides novel insights into the possible biological consequences of cfDNA seen in the advanced cancer state.
Source of Funding: None
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ROLE OF THE C-MYC TARGET DNPH1, A NEW N-HYDROLASE, IN KIDNEY AND PROSTATE CANCERS INTRODUCTION AND OBJECTIVES: Clear cell renal cell carcinoma (CCC), the most lethal urologic tumor (250 000 cases, 110 000 deaths worldwide/year), is the main subtype of kidney cancer. It is characterized in 75% of cases by the loss of the von Hippel-Lindau (VHL) tumor suppressor gene leading to HIFa stabilization. Prostate cancer (PCa) is the most common cancer in men > 50 yo (1 100 000 cases, 300 000 deaths worldwide/year). CCC and PCa are resistant to therapies. DNPH1 (2 0deoxynucleoside 5 0 -phosphate N-hydrolase 1), a c-Myc target overexpressed in various cancers, regulates cell growth and angiogenesis and may thus behave as a new oncogene. Through alternative splicing, 4 isoforms can be generated with still unknown precise function. Our objective was to define the role of DNPH1 in these cancers.
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THE JOURNAL OF UROLOGY â Vol. 197, No. 4S, Supplement, Monday, May 15, 2017 METHODS: We used a panel of cell lines i.e 786-0, A498 (VHL -) and Caki-1, Caki-2, ACHN (VHL +) for CCC and LNCaP, VCap, PC3, DU145, 22RV1 for PCa. Tumor/normal corresponding tissues pairs from 42 and 41 CCC and PCa patients, respectively, were also used. DNPH1 isoforms expression was measured by RTqPCR and Western blot. Since no specific chemical inhibitors are available, the role of DNPH1 isoforms in vitro and in vivo was evaluated using siRNAs and expressing vectors (wild-type or inactive, dead active site). In vivo, we used the tumor xenografted nude mice model to assess the role and the underlying mechanisms of DNPH1 in tumor growth.
RESULTS: We show that CCC and PCa express only isoforms 1 and 2. These are 174 and 148 aminoacids long, respectively, and are identical till aminoacid 126. DNPH1 expression was deregulated in 71% of CCC cases but upregulated in 75% of PCa cases, regardless of the stage. Both isoforms behave similarly but isoform 1 represented 80% of total DNPH1 expression. In CCC cell lines, the transfection with wildtype DNPH1 expressing vectors decreased cell growth up to 60% by stimulating cell proliferation and inhibiting apoptosis, while the transfection with the inactive vector had no effect. In PCa cells, siRNAs targeting DNPH1 isoforms 1 and 2 decreased cell growth dosedependently by up to 50% through inhibition of cell proliferation and induction of apoptosis. We are currently evaluating the effect of both isoforms in nude mice xenografted with CCC cell lines transfected with the DNPH1 expressing vector and in PCa-bearing nude mice treated with in vivo siRNAs. First results corroborate in vitro observations. CONCLUSIONS: Our results show the opposite tumor suppressor/oncogene properties of DNPH1 in CCC and PCa and should allow to design new therapeutic options for these refractory diseases. is amongst the top five in cancer related death in men worldwide. Epidemiologically it varies with race and ethnicity. African American (AA) men not only have a higher incidence rate (~60%), but also~2.5times higher rate of mortality when compared to Caucasian men (CaM). In addition, there is diverse molecular heterogeneity in terms of mutations, gene expression, methylation patterns and copy number alterations in PCa. Therefore, it is of interest to identify the epigenetic and transcriptomic variation in African American and Caucasians.
METHODS: The Cancer Genome Atlas (TCGA) dataset was used to investigate the variation in the biology of prostate cancer patients categorized on the basis of ethnicity. The study included large cohort of 333 primary prostate carcinoma patients that included 43 AA (13%) and 162 CaM (48%). We assessed and analyzed the differential methylation patterns amongst African Americans and Caucasians. Further, the genes that are differentially expressed in each methylation cluster were analyzed to identify the biological pathways that are significantly affected in both the races.
RESULTS: We identified that out of four methylation clusters, AA predominantly belongs to methylation cluster 1 (20.9%) compared to CaM (9.9%). However, CaM (37%) preferentially belongs to methylation cluster 3 than AA (7%). Interestingly, the pathways involved with upregulated genes in methylation cluster 1 were associated with neuronal related pathway whereas, similar pathways were observed to be downregulated in methylation cluster 3. Comparatively, pathways associated with upregulated genes in cluster 3 include inflammation related pathways and hedgehog signaling pathways. Cell cycle signaling, DNA replication and Wnt signaling were predominantly associated with downregulated genes in methylation cluster 1.
CONCLUSIONS: The disparity in the molecular mechanism involved in the pathogenesis of prostate cancers in AA and CaM suggests diverse heterogeneity among different races. Variation of neuronal related pathway in different methylation clusters and their association with AA indicate its crucial role in racial disparity. Enrichment of neuronal signaling may reflect the more aggressive phenotype observed in prostate cancers of AA men. INTRODUCTION AND OBJECTIVES: Surgical prostate cancer bone metastasis samples were collected at the time of orthopaedic repair surgery and used to establish four novel patient-derived xenograft (PDX) models for advanced prostate cancer in the bone: PCSD1, PCSD4, PCSD5 and PCSD13. These PDX models closely reproduced bone metastatic disease in prostate cancer patients. In order to understand the changes that occur which may lead to progressive therapy resistance of the prostate cancer bone metastases we investigated and compared the genomic and transcriptomic variation in the longitudinal series of surgical bone metastasis prostate cancer patient samples and the xenografts derived from them.
Source of
METHODS: We performed copy number variation (CNV) assays on whole genome SNP arrays (Oncoscan, Affymetrix), whole exome DNA sequencing on the Illumina HiSeq 2000 sequencing platform and transcriptome analysis using Affymetrix GeneChip Human Transcriptome Array 2.0 on our PDX models from serial xenograft passages in mice and compared them to their originating patient's bone metastasis samples. We also established microfluidic enrichment of single cells for RNASeq on our PDXs to detect the lethal metastatic clone evolution in the patient and xenograft tumor cells growing in the bone with and without anti-androgen treatment.
RESULTS: Comparison of genome-wide copy number variation (CNV), and whole exome sequencing (WES) revealed selection of a therapy-resistant sub-population -a metastatic clone -in both the patient bone metastases and in the xenograft, PCSD1, derived from the same patient (PDX). This is the first direct evidence that the therapy resistant sub-clone was already present in the heterogeneous early patient bone metastasis. WES analysis revealed germline alterations in DNA repair genes (BRCA2, ATM and CHEK2) in PCSD1, and PCSD5 as well as tumor suppressor genes (TP53, PTEN) in all four PDXs. Enzalutamide or bicalutamide treatment of castrate-resistant intra-femoral PCSD1 xenografts induced expression of a neuronal gene signature.
CONCLUSIONS: We showed for the first time the selection in the patient and in his serially passaged xenografts of a pre-existing, therapy-resistant sub-population in his progressing bone metastatic prostate cancer. We have used our new PDXs for the genomic characterization of the lethal metastatic clones in order to generate a multimarker signature which may be used to detect and therapeutically target lethal metastases early in the disease.
